<DOC>
	<DOCNO>NCT00003176</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness temozolomide carmustine treat patient anaplastic glioma .</brief_summary>
	<brief_title>Temozolomide Carmustine Treating Patients With Anaplastic Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate activity , measure term progression free survival , carmustine plus temozolomide recurrent glioblastoma . II . Estimate response rate recurrent glioblastoma combination . III . Estimate response rate newly diagnose anaplastic astrocytomas mixed anaplastic glioma combination . IV . Evaluate qualitative quantitative toxicity combination patient anaplastic glioma . OUTLINE : This nonrandomized study . Patients stratified disease ( recurrent glioblastoma v anaplastic astrocytoma mixed anaplastic glioma ) . Patients receive carmustine intravenously day 1 two hour prior temozolomide . Temozolomide administer orally day 1 . Cycles repeat every 42 day . Treatment patient recurrent glioblastoma may continue 8 cycle absence disease progression unacceptable toxicity . If disease progression 8 cycle , treatment may continue investigator 's discretion . Patients anaplastic astrocytoma mixed anaplastic glioma continue 4 cycle treatment . Patients follow periodically investigator 's discretion , least twice first 4 month , death . PROJECTED ACCRUAL : A minimum 17 patient maximum 37 patient accrue recurrent glioblastoma stratum 45 patient accrue anaplastic astrocytoma mixed anaplastic glioma stratum .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Recurrent glioblastoma Anaplastic astrocytoma Mixed anaplastic glioma For recurrent glioblastoma : Required documented progression must include increase tumor size least 25 % appearance new lesion For anaplastic astrocytoma mixed anaplastic glioma : Must measurable , contrast enhance disease postoperative CT MRI scan No postoperative radiation chemotherapy If patient receive prior brachytherapy stereotactic radiosurgery , must confirmation true progressive disease rather radiation necrosis PET scan biopsy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,800/mm3 Platelet count least 125,000/mm3 Hemoglobin least 9 g/dL ( transfusion allow ) Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2.0 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 70 mL/min Cardiovascular : No uncontrolled arrhythmia conduction defect No unstable newly diagnose angina pectoris No New York Heart Association class IIIV heart disease No congestive heart failure No major problem edema ( e.g. , severe Cushing 's syndrome , residual leg swell deepvein thrombosis ) No recent coronary artery disease No poorly control hypertension ( diastolic great 110 mmHg systolic great 180 mmHg ) Pulmonary : DLCO great 80 % expect value Other : HIV negative No major psychiatric illness No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient free disease 5 year Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior nitrosourea temozolomide No 1 prior chemotherapy regimen allow patient glioblastoma At least 6 week since mitomycin procarbazine recover At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : If receive steroid , must stable steroid dose least 72 hour prior study No concurrent endocrine therapy Radiotherapy : At least 6 week since radiotherapy No great 1020 % marrow irradiate prior radiotherapy No concurrent radiotherapy Surgery : Surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>